Finance

Lists
Why is 4528 up 2.94%?
Dive Deeper
4528:TYO
Ono Pharmaceutical Co Ltd
¥2,379.00
+2.94%
(+68.00) 1D
Nov 4, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4528...
Open
¥2,348
High
¥2,380
Low
¥2,302
Mkt. cap
1.19T
Avg. vol.
1.94M
Volume
2.62M
Dividend
3.36%
Quarterly dividend
¥20
Ex-dividend date
Sep 29, 2026
P/E ratio
14.98
52-wk high
¥2,674
52-wk low
¥1,868
EPS
¥159
Shares outstanding
514.12M
No. of employees
4K
Open
¥2,348
High
¥2,380
Low
¥2,302
Mkt. cap
1.19T
Avg. vol.
1.94M
Volume
2.62M
Dividend
3.36%
Quarterly dividend
¥20
Ex-dividend date
Sep 29, 2026
P/E ratio
14.98
52-wk high
¥2,674
52-wk low
¥1,868
EPS
¥159
Shares outstanding
514.12M
No. of employees
4K
News stories
From web sources and news partners
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4.21K
Founded1717
HeadquartersOsaka, Osaka, Japan
SectorPharmaceutical industry
Industry-
Last report
Oct 28, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
116.34B / 116.61B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
139.90B
118.75B
116.16B
116.34B
Cost of goods sold
36.68B
33.06B
28.68B
28.75B
Cost of revenue
36.68B
33.06B
28.68B
28.75B
Research and development expenses
33.53B
42.49B
32.40B
36.69B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31.73B
27.70B
23.90B
24.03B
Operating expense
67.00B
77.09B
56.83B
60.34B
Total operating expenses
103.68B
110.15B
85.51B
89.09B
Operating income
36.22B
8.60B
30.65B
27.25B
Other non operating income
-
318.00M
-2.00M
2.00M
EBT including unusual items
37.20B
3.28B
31.25B
27.17B
EBT excluding unusual items
37.20B
8.77B
31.25B
27.17B
Income tax expense
8.31B
2.24B
7.09B
6.30B
Effective tax rate
22.35%
68.23%
22.68%
23.19%
Other operating expenses
1.73B
3.81B
526.00M
-376.00M
Net income
28.86B
818.00M
24.15B
20.78B
Net profit margin
20.63%
0.69%
20.79%
17.86%
Earnings per share
-
-
-
-
Interest and investment income
1.39B
195.00M
1.38B
1.12B
Interest expense
-408.00M
-34.00M
-783.00M
-1.21B
Net interest expenses
979.00M
161.00M
598.00M
-87.00M
Depreciation and amortization charges
-
3.10B
-
-
EBITDA
45.82B
18.21B
39.63B
36.33B
Gain or loss from assets sale
-
2.20B
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps